Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Hectorol (doxercalciferol capsules) in Secondary Hyperparathyroidism
2007-001043-22Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of doxercalciferol in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Sanofi. Primary endpoints: Safety and tolerability of Hectorol capsules over 52 weeks and Efficacy of Hectorol capsules over 52 weeks. Started Sep 2007; status: completed.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-001043-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001043-22.